Uricosuric effect of different doses of irtemazole in normouricaemic subjects.

Abstract

Irtemazole 12.5 to 50 mg in 6 healthy, normouricaemic subjects caused a maximal decrease in plasma uric acid (after 8 to 12 h) of 46.5%. The uricosuric effect began during the first 60 min after drug administration and it lasted for 7 to 24 h. Renal uric acid excretion returned to its base line value after 8 to 16 h and uric acid clearance after 10.0 to 12.0 h. Doses of irtemazole between 12.5 and 37.5 mg produced a dose-related rise in the uricosuric effect. There was no essential difference between the uricosuric effect of 37.5 mg and 50 mg irtemazole. The D50 dose (that producing a half-maximal effect) was between 16.3 mg and 34.2 mg, (average 24.7 mg). The value of irtemazole in the management of hyperuricaemia and gout remains to be determined.

• Authors: U Gresser, I Kamilli, U Kronawitter, N Zöllner
• Journal: European journal of clinical pharmacology (Eur J Clin Pharmacol) Vol. 38 Issue 5 Pg. 489-91 ( 1990) ISSN: 0031-6970 [Print] Germany
• PMID: 2379534 (Publication Type: Journal Article)

Chemical References

• Benzimidazoles
• Uricosuric Agents
• Uric Acid
• irtemazole

Topics

• Adult
• Benzimidazoles (adverse effects, pharmacology)
• Dose-Response Relationship, Drug
• Humans
• Male
• Uric Acid (blood, urine)
• Uricosuric Agents (adverse effects, pharmacology)